The global impact of hepatic fibrosis and end-stage liver disease.
about
Bone marrow derived stem cells for the treatment of end-stage liver diseaseAntifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney FibrosisLiver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cellsLiver fibrosis and mechanisms of the protective action of medicinal plants targeting inflammation and the immune response.Pain management in the cirrhotic patient: the clinical challenge.Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosisThe role of mutations in core protein of hepatitis B virus in liver fibrosisHepatic Artery and Portal Vein Doppler Indexes in Non-alcoholic Fatty Liver Disease Before and After Treatment to Prevent Unnecessary Health Care Costs.High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism.Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis.Pharmacotherapy for alcoholic patients with alcoholic liver diseaseEconomic burden of hepatitis C-associated diseases in the United States.ADV36 adipogenic adenovirus in human liver disease.Gut-liver axis improves with meloxicam treatment after cirrhotic liver resectionAssociation of serum α-tocopherol, β-carotene, and retinol with liver cancer incidence and chronic liver disease mortality.Diffusion-weighted magnetic resonance imaging for the staging of liver fibrosis.Hepatoprotective herbs, avicenna viewpoint.Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation.Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis.Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-AnalysisEvaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T.Health-related quality of life (HRQOL) in children with chronic liver disease in North East Iran using PedsQL™ 4.0.Somatic survival and organ donation among brain-dead patients in the state of QatarEpigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis.Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling PathwaysConsilience in sarcopenia of cirrhosis.Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis.Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesUpdate on the management of cirrhosis - focus on cost-effective preventative strategiesNursing Assessment Tool for People With Liver CirrhosisModulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells.Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.Venous Outflow Reconstruction in Adult Living Donor Liver Transplant: Outcome of a Policy for Right Lobe Grafts without the Middle Hepatic Vein.Signals and cells involved in regulating liver regeneration.In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis.Clinical, epidemiological characteristics and indications for liver biopsy and treatment in immigrants with chronic hepatitis B at a referral hospital in Madrid.Dendritic cells in alcoholic liver injury and fibrosis.The role of the renin-angiotensin system in liver fibrosis.Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.
P2860
Q26850412-37C92501-55FE-4E70-A7FB-19DF86633D32Q27336127-2A976711-A26C-49E9-B72B-2575540B0570Q30369750-C375B02B-0DA7-43EC-8E41-1E340F4AE0BFQ30374500-11303462-5E4D-496A-98E3-5DC46C515FEEQ30494286-53373127-E7B1-4EE8-AA2E-9338DFA79025Q30496270-E6D69BDA-C9F7-4D08-8D8C-06791F2B3A45Q33567791-D2E76B90-FAD5-4148-BC64-636DFE476A1AQ33600668-2C57DFEE-7C5B-40CB-807E-B9EC03F96456Q33896110-11B6D311-5014-4601-AF30-896A206824FBQ34017968-FEE71B8E-E5B9-46F2-A5F2-4B60A3679E03Q34223054-25A231C4-2F91-414F-BD38-12A98E64D236Q34253963-B10B4700-23C4-4BED-8116-D44C8D9C70B3Q34405050-41658C24-0E52-475B-9804-527D5AC3A202Q34405116-1DC740DF-EC0E-4BEA-8520-E39D715F9B0FQ34658195-97955E9A-DFE7-497F-A356-1329A71AA71BQ35111929-E3E9CF3A-5089-44D1-8103-4442721DDBDEQ35144480-253AC079-BD63-4705-B665-22FC05C59836Q35586755-C69B3841-0E93-4229-9AEA-CA1ECAD21897Q35780081-B4306581-001D-42C4-87D5-484E11FE15D3Q35964652-F372DB79-28CE-4BE5-8F55-9A6A4BCA8442Q35965015-784AD2CA-BD08-4679-913A-A8BE1FC05E7DQ36059493-20C5A0C8-A67F-4631-A81B-9D6B045DE91FQ36082379-9A27FAC8-7FF3-4487-832D-928E8019B932Q36178736-B8B94833-59C6-4289-B510-197BB81F65A2Q36217669-632B3C99-C7F0-4F97-8BD5-4D72DD578079Q36376464-B803D091-A071-4C16-9011-57C3FB0333DCQ36421047-27165223-E665-4DD1-82CC-3CEE0D8E97F3Q36698776-02D3826C-258A-47C5-BB41-F9DC20F904D6Q36756206-BB5D73BE-094E-432D-9493-EF87D13C35C7Q36784836-E8CFF82D-63FC-4C52-BED9-AE5F4DF03D0DQ37143408-922F650A-A40D-40E0-9DAA-10F555AA0785Q37192466-03FBF441-702A-4630-8EFC-0E67C327835BQ37316860-B1934E58-30AD-47DB-8901-0B8DFAA1F881Q37482358-4A088DC1-0E35-4438-B40E-70AD5E179255Q37512367-4E07D04D-92B3-4548-8340-3164897520C2Q37666051-CAAC6FA2-2AA5-4FCA-A093-5C2ADB70A964Q37724455-31826711-2ADC-47C9-A9B0-3F9CC40A70E6Q37834041-1876D294-12F0-4A9D-87B8-5D3DCF57B642Q37867350-398A0B48-DF57-4728-B91C-8365B6DDBED8Q38018841-15AAA87C-C6AB-4326-9DF1-08563CB39192
P2860
The global impact of hepatic fibrosis and end-stage liver disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The global impact of hepatic fibrosis and end-stage liver disease.
@en
The global impact of hepatic fibrosis and end-stage liver disease.
@nl
type
label
The global impact of hepatic fibrosis and end-stage liver disease.
@en
The global impact of hepatic fibrosis and end-stage liver disease.
@nl
prefLabel
The global impact of hepatic fibrosis and end-stage liver disease.
@en
The global impact of hepatic fibrosis and end-stage liver disease.
@nl
P1476
The global impact of hepatic fibrosis and end-stage liver disease
@en
P2093
Young-Suk Lim
P304
733-46, vii
P356
10.1016/J.CLD.2008.07.007
P50
P577
2008-11-01T00:00:00Z